No price history available for this symbol yet.
Held by
0
portfolios on TandT
Bookmarked by
0
users
Avg position size
—
of holders' portfolios
13F filers
0
institutions
Sector
Biotechnology
EirGenix Inc., founded in 2012 and based in New Taipei City, Taiwan, functions as a contract development and manufacturing organization (CDMO) with operations spanning both domestic and international markets. The company offers a comprehensive range of services, encompassing cell line creation, process optimization, analytical testing and quality control, and current Good Manufacturing Practice (cGMP) compliant production utilizing both mammalian and microbial expression systems. They also specialize in services related to antibody-drug conjugates (ADCs). Beyond its service offerings, EirGenix is actively engaged in developing several therapeutic candidates. This pipeline includes EG12014/EGI014, a Trastuzumab biosimilar intended for cancer therapy, which has reached the biologics license application (BLA) submission stage. Other oncology-focused developments are EG1206A, a Pertuzumab biosimilar currently in Phase I clinical trials; EG13074, in preclinical development; and TSY0110(EG12043), an antibody-drug conjugate also in preclinical stages. Additionally, the company is advancing EG12021, a Bevacizumab biosimilar for cancer treatment, and EG62054, another biosimilar, both in preclinical development. In addition to its core activities, EirGenix manufactures and distributes a rapid antigen test for COVID-19, as well as the CRM197 carrier protein under the designation EG74032.
www.eirgenix.comNo one on the platform currently holds 6589.TWO.
No tracked institution reports a position in 6589.TWO as of their last filing.
No one on the platform has traded 6589.TWO yet.
Consensus-seeded revenue, margins, and exit multiples. This is a scenario tool, not investment advice.
Consensus does not cover every selected forecast year. Later assumptions are extrapolated from available analyst estimates.
| Metric | Historical average | My assumptions | ||||
|---|---|---|---|---|---|---|
| 1 year | 5 years | 10 years | Low | Mid | High | |
| Rev. Growth % | -0.4% | -1.3% | ||||
| Profit Margin % | -75.7% | -48.9% | ||||
| Free Cash Flow Margin % | -89.9% | -88.4% | ||||
| Exit P/E | — | — | — | |||
| Exit P/FCF | — | — | — | |||
| Desired Annual Return % | — | — | — | |||
At today's price, your expected annual return is — on the P/E track.
At today's price, your expected annual return is — on the P/E track.
At today's price, your expected annual return is — on the P/E track.
No recent Form 4 filings on EDGAR — either no insider transactions reported recently or this isn't a SEC-registered issuer.
| Year | Est. revenue | Growth | Est. EPS | EPS range | Fwd P/E | # Analysts |
|---|---|---|---|---|---|---|
| 2026 | $1.5B | +17.8% | $-1.52 | $-1.52–$-1.52 | — | 1 |
| 2027 | $2.3B | +59.0% | $0.57 | $0.57–$0.57 | — | 1 |
Forward consensus · growth is YoY vs the prior fiscal-year estimate · Fwd P/E at the current price · source: Financial Modeling Prep
Beat consensus in 5 of the last 8 reported quarters
| Reported | Est. EPS | Actual | Surprise |
|---|---|---|---|
| 2026-05-12 | $-0.54 | $-0.47 | +13.0% |
| 2026-03-09 | $-0.03 | $-0.57 | -1800.0% |
| 2025-08-08 | $-0.52 | $-1.23 | -136.5% |
| 2025-05-13 | $-0.56 | $-0.52 | +7.1% |
| 2025-03-12 | $-0.46 | $-0.38 | +17.4% |
| 2024-11-12 | $-0.86 | $-0.84 | +2.3% |
| 2024-08-08 | $-0.42 | $-0.72 | -71.4% |
| 2024-05-09 | $-0.35 | $-0.34 | +2.9% |
| -0.36% |
| $7.8B |
| — |
| 4174.TWOOBI Pharma, Inc. | $26.65 | +2.50% | $3.5B | — |
| 4726.TWOMycenax Biotech Inc. | $22.45 | -0.66% | $4.6B | — |
Source: Financial Modeling Prep · peers by sector/industry